查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1844149

摄护腺癌核医诊断市场（依放射性药物、模式、最终使用者和适应症划分）－2025-2032年全球预测

Prostate Cancer Nuclear Medicine Diagnostics Market by Radiopharmaceutical, Modality, End User, Indication - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，摄护腺癌核医诊断市场规模将达到 31.2 亿美元，复合年增长率为 13.19%。

主要市场统计数据
基准年 2024 11.5亿美元
预计年份：2025年 13.1亿美元
预测年份：2032年 31.2亿美元
复合年增长率 (%) 13.19%

临床、技术和商业性力量的融合正在重塑用于前列腺癌治疗的核医学诊断。

由于分子影像技术的进步、临床诊疗途径的不断发展以及跨学科合作的日益密切，前列腺癌核医学诊断的临床和技术格局正在发生显着变化。过去以传统影像学方法为主的诊断方法，如今正逐步引入更灵敏的放射性药物和混合影像平台，以实现更精准的定位、分期和復发检测。因此，临床医生和医疗系统正在重新评估诊断流程，以优化患者分层和治疗决策。

在临床应用的同时，对影像基础设施、放射化学能力和人才队伍建设的投资正在重塑医疗服务提供者的营运考量。放射性药物的创新与扫描仪硬体和软体的改进相辅相成，提高了影像品质和通量，从而能够更可靠地检测低丰度疾病。同时，包括生物製药公司、设备製造商和学术中心在内的相关人员正在累积临床效用和健康结果方面的证据，这些证据反映在与支付方的沟通以及治疗路径的整合中。

展望未来，法律规范、报销政策和供应链韧性之间的相互作用将决定这些创新成果转化为日常实践的速度。对于那些希望影响临床实践并创造价值的机构而言，策略伙伴关係和数据主导的方法正变得至关重要。在此背景下，了解推动技术应用的技术、临床和商业性因素，对于希望引领前列腺癌核医学诊断下一阶段发展的管理者、临床医生和投资者至关重要。

探讨能够提高诊断准确性并重新定义前列腺癌影像通道的关键技术和临床曲折点

近年来，核子医学在前列腺癌检测领域发生了变革性变化，正在改变诊断流程和相关人员的预期。针对前列腺特异性膜抗原（PSMA）的显影剂的成熟，拓宽了临床医师的选择范围，提高了病灶检出率，降低了疾病负荷，并促使人们重新评估影像学检查的适应症。放射化学的同步发展使<sup>18</sup>F标记的显影剂在操作上比基于发生器的同位素更具优势，而新型同位素的出现则进一步丰富了诊断和潜在治疗套件。

同时，成像硬体和分析平台也取得了长足进展。飞行时间子断层扫描（TOF-PET）和数位正子断层扫描（D-PET）提高了空间解析度和灵敏度，不仅增强了诊断的可靠性，还缩短了扫描时间并降低了辐射剂量。虽然混合式SPECT/CT在某些适应症中仍然有效，但整体发展趋势倾向于以PET为中心的工作流程，因为临床证据表明，PET能够提高诊断产量。定量影像指标和人工智慧辅助后处理的整合正在逐步规​​范报告流程，并减少阅片者之间的差异，从而加强影像输出与临床决策之间的连结。

在政策和商业领域，报销管道正随着临床证据的不断累积而演变，但不同支付方和地区之间存在差异。随着製造商、放射药物供应商和医疗服务提供者着手解决物流、低温运输管理和生产规模化等问题，供应链因素的重要性日益凸显。总体而言，这些转变反映了精准诊断的广泛趋势，即整合影像学检查方式、药物选择和临床意图，为前列腺癌的个人化治疗提供可操作的资讯。

新的贸易措施如何推动核医学诊断领域的策略供应链调整、生产在地化和采购创新

贸易当局实施的新关税对支撑核医学诊断的复杂全球供应链产生了重大影响。对关键组件、试剂和成品放射性药物征收的关税会影响製造商、放射性药物工厂和影像中心的采购决策。随着进口关税的增加，企业面临更高的到岸成本，被迫重新评估筹资策略，以维持服务的连续性和竞争优势。

为了应对关税带来的成本压力，企业和医疗系统可能会将生产本地化并加强本地合作。投资国内放射化学品生产能力和区域分销网络将变得更具吸引力，以此作为对冲贸易摩擦的手段。此外，製造商可能会加快对可在本地生产的替代同位素和标记化学品进行认证的步伐，或减少对受关税影响的投入品的依赖。这些调整将有助于降低风险，但需要资金、前置作业时间和与监管机构的协调。

在营运层面，影像服务提供者必须应对采购、库存和合约调整等一系列挑战。长期合约、供应商多元化以及与学术中心和第三方迴旋加速器营运商的密切合作可以降低成本波动带来的风险。从策略角度来看，贸易相关的成本转移也会影响成本效益评估和与支付者的谈判。最终，关税将成为供应链重组的催化剂，促使各方采取措施增强供应链的韧性，并专注于加强商业、临床和监管等相关人员之间的协调。

将放射性药物选择、成像方式能力、医疗环境属性和临床适应症与可操作的诊断策略联繫起来的精细分割洞察

该报告的洞察揭示了放射性药物类别、影像方式、医疗环境和临床适应症之间的差异化动态，从而为部署策略提供基础。基于放射性药物，报告研究了<sup>11</sup>C 胆碱、<sup>18</sup>F DcfpyL、<sup>18</sup>F 氟西克洛韦、<sup>68</sup>Ga PSMA 和新兴药物的市场情况，其中新兴药物包括<sup>18</sup>F PSMA 1007 和<sup>64</sup>Cu PSMA。按影像方式划分，报告研究了 PET 和 SPECT 的市场情况，其中 PET 进一步细分为数位 PET 和 TOF PET，SPECT 则细分为传统 SPECT 和 SPECT CT。按最终用户划分，报告研究了学术研究机构、诊断中心和医院的市场状况。这种细分突显了营运规模、临床复杂性和现场放射化学资源取得的差异，这些差异反过来又会影响技术的采用时间。按适应症划分，报告研究了生化復发检测、早期分期和治疗监测的市场情况。根据这些适应症选择合适的药物和治疗方式，可以最大限度地提高诊断产量和临床效用。

了解这些环节如何交织至关重要。例如，高灵敏度PET显影剂与数位PET扫描仪的结合，在以检测生化復发为重点的场景中尤其重要，但这种结合需要对影像基础设施和可靠的放射性药物供应进行投资。相反，提供综合肿瘤服务的医院可以利用院内放射化学资源和策略性供应协议，优先选择能够支援分期和治疗监测流程的显影剂和影像方式。学术研究机构在检验新显影剂和完善临床通讯协定发挥关键作用。将临床问题与合适的显影剂、影像方式和临床环境结合，有助于相关人员优化诊断流程和资源分配。

从区域观点影响先进核子医学诊断技术取得和全球应用的监管、基础设施和支付方驱动因素

区域动态，尤其是法规环境、基础设施能力和支付框架的差异，对先进核医学诊断技术的采纳和广泛应用有显着影响。在美洲，临床应用主要得益于一流的医疗设施、完善的放射性药物网络以及对影像结果与治疗决策之间关联证据的日益重视。在欧洲、中东和非洲，情况则较为复杂，一些国家能够迅速整合先进的PET显像剂和最新的扫描仪技术，而另一些国家则由于基础设施和报销政策的差异而面临应用受限的问题。在亚太地区，对影像基础设施的大力投资、训练有素的专家数量的增加以及战略性的行业联盟正在加速技术的普及，但放射性药物的配送和监管协调等物流问题仍然是需要优先考虑的事项。

为了从区域观察走向实际行动，相关人员在规划商业化和市场进入策略时，必须考虑每个区域独特的有利因素和限制因素。供应链设计、监管沟通以及支付方证据的收集都必须根据当地实际情况进行调整。此外，利用区域临床卓越中心进行价值论证和最佳实践推广，可以促进不同医疗保健系统之间更公平的医疗服务取得和一致的医疗服务标准。

开发商、设备供应商、放射药业和临床中心之间透过策略竞争与合作，推动临床检验和市场准入。

核子医学诊断领域的竞争动态反映了专业放射性药物开发商、影像设备製造商、商业性放射性药物製造商和学术研究联盟之间的整合。放射性药物开发商投资于临床试验和生产规模化，以确保临床应用；影像设备供应商则专注于硬体和软体创新，以提高灵敏度和易用性。商业性放射性药物製造商和第三方迴旋加速器营运商的重要性日益凸显，因为他们提供的分散式生产解决方案降低了不具备现场生产能力的诊所的准入门槛。

合作研究和策略联盟在推动临床证据和市场进入方面发挥核心作用。研发供应商通常与学术中心合作检验临床终点，或与影像供应商合作优化药物与扫描器的兼容性。同时，诊断中心和医院开展试验计画，以展示工作流程整合、成本影响和病患疗效。监管策略和与支付方的沟通仍然是区分企业优劣的关键。积极开发可靠的比较证据和健康结果证据的公司，在与保险公司谈判保险覆盖范围以及将其技术整合到临床管道方面更具优势。从商业性角度来看，提供整合药物供应、影像系统和服务支援的捆绑式解决方案的公司，可以简化医疗服务提供者的流程，并建立更牢固的客户关係。

为领导者制定优先行动方案，以加速证据产生、供应链韧性、支付方参与、营运准备和推广应用。

产业领导者若想充分利用摄护腺癌核医领域的进展，应制定一套协调一致的策略，将临床证据的产生、供应链的韧性、与支付者的互动结合。首先，应优先进行能够影响决策终点的临床研究，例如影像技术如何改变行政流程以及最终的患者预后。其次，应投资于灵活的生产和分销模式，包括与区域迴旋加速器营运商和商业性放射性药房建立合作关係，以降低贸易和物流中断的风险。

同时，我们将加快采用已确立临床效用的先进影像处理硬体和分析技术，并将资本投资与营运培训计划相结合，以确保高效利用。我们将积极与支付方和卫生技术评估机构合作，提供反映真实工作流程的实用证据和卫生经济学分析。我们将与价值链上的开发商、影像处理供应商、医疗服务提供者和病患权益倡导组织建立策略联盟，以製定整合的价值提案，减少实施阻力。最后，我们将制定数位资料策略，以实现长期结果追踪和真实世界证据的产生。这些能力将支持持续改进、监管互动和商业化工作。这些措施将为临床影响和可持续的商业性绩效奠定坚实的基础。

透过透明的多源研究途径，结合专家访谈、同侪审查的证据综合和迭代检验，获得可靠的洞见。

这些研究成果的依据是：结合了对同侪审查文献、监管指南和公开临床试验註册库的实证综述，以及对来自临床、生产和商业营运领域的专家进行的结构化访谈。主要研究包括与核子医学从业人员、放射药剂师和影像操作负责人进行定性讨论，以了解实际工作流程中的考虑因素、应用障碍以及技术性能的权衡取舍。次要研究则综合分析了技术白皮书、共识指南和产品文檔，以揭示各种影像方式的功能和药物特性。

调查方法结果经过多资讯来源三角检验，并透过与方法学家和领域专家反覆磋商加以完善。资料品管包括交叉核对不同来源资料、协调相互矛盾的讯息，并着重于临床效用终点而非专有商业性指标。研究方法优先考虑方法学的透明度和研究结果的可重复性，以支持临床领导者、製造商和政策制定者做出可靠的决策。针对证据缺口，分析确定了优先研究方向，并建议了能够有效填补这些缺口的研究设计。

本文简要概述了技术创新、营运韧性和主导商业化将如何融合，从而塑造前列腺癌诊断的未来。

放射性药物、影像硬体和分析技术的进步共同提升了核子医学诊断在前列腺癌治疗中的作用。这些进展能够更精准地检测病灶，改善临床决策，并为诊断与治疗计划的更紧密结合铺平道路。同时，贸易政策的变化和日益复杂的供应链凸显了战略韧性和在地化能力的重要性。由此形成了一个快速发展的生态系统，该系统必须将技术创新与切实可行的商业化策略、实证医学证据的产生以及与支付方的沟通协调起来。

显然，价值链上的相关人员迫切需要将临床优先事项与营运实际情况和打入市场策略相协调。投资于可靠的临床检验、确保多元化且具有韧性的供应链，以及向支付方和医疗服务提供者阐明清晰的价值命题，可以帮助企业加速将诊断创新转化为改善患者预后的成果。医疗机构间的协作和数据共用将进一步加快技术应用和一致性治疗的步伐。最终，在临床、商业和物流领域进行周密的执行将决定哪些创新技术能够在前列腺癌诊断领域产生有意义且持久的影响。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将PSMA标靶PET影像技术应用于復发性摄护腺癌的早期检测与分期
  • 放射性标记小分子疗法的进步改善了转移性去势抵抗性前列腺癌（mCRPC）靶向放射性核素治疗的疗效。
  • 推出新一代数位PET/CT扫描仪，以提高前列腺癌诊断的影像解析度和定量准确性
  • 一种新型PSMA标靶放射性核种偶联物在治疗诊断前列腺癌患者的应用：监管核准与商业化
  • 混合型PET/MRI系统的发展旨在减少辐射暴露，同时提高前列腺成像中软组织表征的准确性
  • 新兴人工智慧演算法在核医前列腺癌检查中的自动解读和预后风险分层的应用
  • 在临床实务中，个人化剂量测定软体的应用日益广泛，旨在优化镏-177放射性配体疗法的安全性和有效性。
  • 学术界与製药公司的合作加速了新型α射线PSMA疗法在前列腺癌治疗的临床试验。

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

第八章 摄护腺癌核医诊断剂市场（依放射性药物划分）

  • 11C Choline
  • 18F DcfpyL
  • 18F Fluciclovine
  • 68Ga Psma
  • 新兴代理人
    • 18F Psma 1007
    • 64Cu Psma

第九章 摄护腺癌核医诊断剂市场（依模式划分）

  • PET
    • 数字PET
    • TOF PET
  • SPECT
    • 常规SPECT
    • SPECT CT

第十章 摄护腺癌核子医学诊断剂市场（依最终用户划分）

  • 学术研究机构
  • 诊断中心
  • 医院

第十一章 摄护腺癌核子医学诊断剂市场（依适应症划分）

  • 生化復发检测
  • 初始阶段
  • 治疗监测

第十二章 摄护腺癌核子医学诊断剂市场（按地区分列）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 摄护腺癌核医诊断剂市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国前列腺癌核医诊断剂市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • GE HealthCare Technologies Inc.
    • Siemens Healthineers AG
    • Koninklijke Philips NV
    • Cardinal Health, Inc.
    • Bayer AG
    • Lantheus Holdings, Inc.
    • Bracco Imaging SpA
    • Telix Pharmaceuticals Limited
    • Eckert & Ziegler Strahlen-und Medizintechnik AG
    • Isotope Technologies Munich SE
Product Code: MRR-ED54C46E821C

The Prostate Cancer Nuclear Medicine Diagnostics Market is projected to grow by USD 3.12 billion at a CAGR of 13.19% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.15 billion
Estimated Year [2025] USD 1.31 billion
Forecast Year [2032] USD 3.12 billion
CAGR (%) 13.19%

A thoughtful orientation to the converging clinical, technical, and commercial forces reshaping nuclear medicine diagnostics for prostate cancer care

The clinical and technological landscape of nuclear medicine diagnostics for prostate cancer is undergoing a significant transformation driven by advances in molecular imaging, evolving clinical pathways, and increasing interdisciplinary collaboration. Historically anchored in conventional imaging modalities, diagnostic practice now incorporates higher-sensitivity radiopharmaceuticals and hybrid imaging platforms that deliver more precise localization, staging, and recurrence detection. As a result, clinicians and health systems are re-evaluating diagnostic algorithms to optimize patient stratification and therapeutic decision-making.

Alongside clinical adoption, investments in imaging infrastructure, radiochemistry capabilities, and workforce training are reshaping operational considerations for providers. Radiopharmaceutical innovation is complemented by improvements in scanner hardware and software that enhance image quality and throughput, enabling more reliable detection of small-volume disease. Simultaneously, stakeholders across biopharma, device manufacturing, and academic centers are generating evidence on clinical utility and health outcomes, which in turn informs payer dialogues and pathway integration.

Looking forward, the interplay between regulatory frameworks, reimbursement policies, and supply chain resilience will determine how rapidly these innovations translate into routine care. Strategic partnerships and data-driven approaches are becoming essential for organizations that aim to influence clinical practice and capture value. In this context, understanding the technical, clinical, and commercial vectors that drive adoption is critical for executives, clinicians, and investors seeking to navigate the next phase of nuclear medicine diagnostics for prostate cancer.

An examination of the pivotal technological and clinical inflection points that are accelerating diagnostic precision and redefining imaging pathways for prostate cancer

Recent years have seen transformative shifts in prostate cancer nuclear medicine that are altering diagnostic pathways and stakeholder expectations. The maturation of prostate-specific membrane antigen-targeted agents has expanded options for clinicians, improving lesion detection at lower disease burdens and prompting reappraisal of imaging indications. Parallel advances in radiochemistry have enabled 18F-labeled agents to offer logistical advantages over generator-based isotopes, while the emergence of novel isotopes broadens the diagnostic and potential theranostic toolkit.

Concurrently, imaging hardware and analytical platforms have progressed. Time-of-flight and digital PET capabilities deliver higher spatial resolution and sensitivity, which not only improve diagnostic confidence but also reduce scan durations and dose requirements. Hybrid SPECT/CT remains relevant for specific indications, yet the overall momentum favors PET-centric workflows where clinical evidence supports incremental diagnostic yield. Integration of quantitative imaging metrics and AI-enabled post-processing is beginning to standardize reporting and reduce inter-reader variability, thereby strengthening the link between imaging outputs and management decisions.

In the policy and commercial arenas, reimbursement pathways are evolving in response to accumulating clinical evidence, though variability persists across payers and geographies. Supply chain considerations have risen to prominence as manufacturers, radiopharmacies, and providers respond to logistics, cold-chain management, and production scalability. Taken together, these shifts reflect a broader movement toward precision diagnostics that align imaging modality, agent selection, and clinical intent to yield actionable information for personalized prostate cancer care.

How new trade measures are prompting strategic supply chain adaptation, production regionalization, and procurement innovation across nuclear medicine diagnostics

The introduction of new tariff measures by trade authorities has material implications for the complex, global supply chains that underpin nuclear medicine diagnostics. Tariffs applied to key components, reagents, and finished radiopharmaceuticals influence procurement decisions across manufacturers, radiopharmacies, and imaging centers. When import duties rise, organizations confront higher landed costs and the need to reassess sourcing strategies to preserve service continuity and competitive positioning.

In response to tariff-driven cost pressures, companies and health systems are likely to pursue greater regionalization of production and strengthened local partnerships. Investments in domestic radiochemistry capacity and regional distribution networks become more attractive as a hedge against trade friction. Moreover, manufacturers may accelerate efforts to qualify alternative isotopes or labeling chemistries that can be produced locally or that rely less on tariff-affected inputs. Such adaptations help mitigate exposure but require capital, lead time, and regulatory coordination.

Operationally, imaging providers must navigate a mix of procurement, inventory, and contractual adjustments. Longer-term contracts, diversified supplier bases, and closer alignment with academic centers or third-party cyclotron operators can reduce vulnerability to cost volatility. From a strategic standpoint, trade-related cost shifts also influence cost-effectiveness assessments and payer negotiations, particularly where higher acquisition costs are not matched by demonstrable reductions in downstream expenditures. Ultimately, tariffs act as a catalyst for supply chain reconfiguration, encouraging resilience-building measures while placing a premium on coordination across commercial, clinical, and regulatory stakeholders.

Granular segmentation insights that connect radiopharmaceutical selection, imaging modality capabilities, care setting attributes, and clinical indication to actionable diagnostic strategies

Segmentation-based insights reveal differentiated dynamics across radiopharmaceutical categories, imaging modalities, care settings, and clinical indications that inform deployment strategies. Based on Radiopharmaceutical, the market is studied across 11C Choline, 18F DcfpyL, 18F Fluciclovine, 68Ga PSMA, and Emerging Agents, with the Emerging Agents further examined across 18F PSMA 1007 and 64Cu PSMA; each agent class exhibits unique production, logistical, and clinical adoption characteristics that affect where and how they are implemented. Based on Modality, the market is studied across PET and SPECT, with PET further divided into Digital PET and Time Of Flight PET and SPECT subdivided into Conventional SPECT and SPECT CT; these distinctions highlight trade-offs between resolution, throughput, and capital requirements that facilities must weigh. Based on End User, the market is studied across Academic Research Institutes, Diagnostic Centers, and Hospitals; this segmentation underscores differences in operational scale, clinical complexity, and access to on-site radiochemistry that shape adoption timelines. Based on Indication, the market is studied across Biochemical Recurrence Detection, Initial Staging, and Treatment Monitoring; aligning agent and modality selection to these indications maximizes diagnostic yield and clinical utility.

Understanding how these segments intersect is essential. For example, highly sensitive PET agents paired with digital PET scanners can be particularly impactful in settings focused on biochemical recurrence detection, but such pairings require investment in imaging infrastructure and reliable radiopharmaceutical supply. Conversely, hospitals with integrated oncology services may prioritize agents and modalities that support both staging and treatment monitoring workflows, leveraging in-house radiochemistry or strategic supplier agreements. Academic research institutes play a pivotal role in validating emerging agents and refining clinical protocols, thereby influencing downstream adoption across diagnostic centers and hospitals. By mapping clinical questions to the right combination of agent, modality, and care setting, stakeholders can optimize diagnostic pathways and resource allocation.

Region-specific perspectives on regulatory, infrastructural, and payer drivers that shape access and adoption of advanced nuclear medicine diagnostics globally

Regional dynamics exert a strong influence on the adoption and diffusion of advanced nuclear medicine diagnostics, shaped by differences in regulatory environments, infrastructure capacity, and payer frameworks. In the Americas, clinical uptake has been driven by centers of excellence, an established radiopharmacy network, and a growing emphasis on evidence that links imaging outcomes to therapeutic decision-making; consequently, early adoption clusters often emerge around academic hospitals and specialized cancer centers. Across Europe, Middle East & Africa, the landscape is heterogeneous, with some countries showing rapid integration of advanced PET agents and modern scanner technologies while others face constrained access due to infrastructure or reimbursement variability; collaboration between regional hubs and national health systems plays an important role in expanding access. In the Asia-Pacific region, strong investments in imaging infrastructure, increasing numbers of trained specialists, and strategic industrial partnerships are accelerating adoption, though logistical considerations for radiopharmaceutical distribution and regulatory harmonization remain ongoing priorities.

Transitioning from regional observation to action, stakeholders should consider the unique enablers and constraints of each geography when planning commercialization and access strategies. Supply chain design, regulatory engagement, and payer evidence-generation must be tailored to regional realities. Moreover, leveraging regional centers of clinical excellence to demonstrate value and disseminate best practices can expedite more equitable access and consistent standards of care across diverse healthcare systems.

Strategic competitive and collaborative behaviors among developers, equipment vendors, radiopharmacies, and clinical centers that drive clinical validation and market access

Competitive dynamics within the nuclear medicine diagnostics space reflect a blend of specialized radiopharmaceutical developers, imaging equipment manufacturers, commercial radiopharmacies, and academic research consortia. Radiopharmaceutical developers are investing in clinical trials and manufacturing scale-up to secure clinical uptake, while imaging systems vendors focus on hardware and software innovations that improve sensitivity and usability. Commercial radiopharmacies and third-party cyclotron operators are increasingly important as they provide distributed production solutions that lower barriers to entry for clinics without on-site manufacturing capacity.

Collaborations and strategic alliances are central to advancing both clinical evidence and market access. Developers often partner with academic centers to validate clinical endpoints and with imaging vendors to optimize agent-scanner compatibility. Meanwhile, diagnostic centers and hospitals form pilot programs to demonstrate workflow integration, cost implications, and patient outcomes. Regulatory strategy and payer engagement remain differentiating activities: organizations that proactively generate robust comparative and health outcomes evidence are better positioned to negotiate coverage and embed their technologies into clinical pathways. From a commercial perspective, companies that offer bundled solutions-combining agent supply, imaging systems, and service support-can simplify adoption for providers and create stickier customer relationships.

A prioritized playbook for leaders that aligns evidence generation, supply chain resilience, payer engagement, and operational readiness to accelerate adoption

Industry leaders seeking to capitalize on advances in prostate cancer nuclear medicine should pursue a coherent strategy that aligns clinical evidence generation, supply chain resilience, and payer engagement. First, prioritize clinical studies that address decision-impact endpoints, such as how imaging alters management pathways and downstream patient outcomes; these data are the currency that informs reimbursement and guideline inclusion. Second, invest in flexible manufacturing and distribution models, including partnerships with regional cyclotron operators and commercial radiopharmacies, to reduce exposure to trade and logistical disruption.

In parallel, accelerate adoption of advanced imaging hardware and analytics where clinical benefit is established, but pair capital investment with operational training programs to ensure efficient utilization. Engage proactively with payers and health technology assessment bodies by presenting pragmatic evidence packages and health-economic narratives that reflect real-world workflows. Foster strategic alliances across the value chain-linking developers, imaging vendors, providers, and patient advocacy groups-to create integrated value propositions that lower adoption friction. Finally, embed digital data strategies that enable longitudinal outcome tracking and real-world evidence generation; such capabilities support continuous improvement, regulatory interactions, and commercialization efforts. Together, these measures create a durable foundation for clinical impact and sustainable commercial performance.

A transparent, multi-source research approach combining primary expert interviews, peer-reviewed evidence synthesis, and iterative validation to ensure robust insights

The research underpinning these insights combined an evidence-based review of peer-reviewed literature, regulatory guidance, and publicly available clinical trial registries with structured interviews of domain experts across clinical, manufacturing, and commercial functions. Primary research included qualitative discussions with practicing nuclear medicine physicians, radiopharmacists, and imaging operations leads to capture real-world workflow considerations, adoption barriers, and technology performance trade-offs. Secondary research synthesized technical white papers, consensus guidelines, and product documentation to characterize modality capabilities and agent properties.

Findings were validated through triangulation across multiple sources and refined by iterative consultation with methodologists and subject matter experts. Data quality control measures included source cross-checking, reconciliation of conflicting inputs, and a focus on clinical utility endpoints rather than proprietary commercial metrics. The research approach prioritized transparency in methodology and reproducibility of findings to support robust decision-making by clinical leaders, manufacturers, and policymakers. Where gaps in evidence existed, the analysis identified research priorities and recommended study designs to close those gaps efficiently.

A concise synthesis of how technological innovation, operational resilience, and evidence-driven commercialization converge to shape future prostate cancer diagnostics

Advances in radiopharmaceuticals, imaging hardware, and analytic technologies are collectively elevating the role of nuclear medicine diagnostics in prostate cancer care. These developments enable more precise lesion detection, improve clinical decision-making, and open pathways for closer integration of diagnostics with therapeutic planning. At the same time, trade policy shifts and supply chain complexities underscore the need for strategic resilience and localized capabilities. The net effect is a rapidly evolving ecosystem in which technical innovation must be matched by pragmatic commercialization strategies, evidence generation, and payer engagement.

For stakeholders across the value chain, the imperative is clear: align clinical priorities with operational realities and market access strategies. By investing in robust clinical validation, securing diversified and resilient supply chains, and articulating clear value propositions to payers and providers, organizations can accelerate the translation of diagnostic innovation into improved patient outcomes. Collaboration and data-sharing across institutions will further amplify the pace of adoption and the consistency of care. Ultimately, thoughtful execution across clinical, commercial, and logistical domains will determine which innovations achieve meaningful, sustained impact in prostate cancer diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of PSMA-targeted PET imaging in early detection and staging of recurrent prostate cancer
  • 5.2. Advances in radiolabeled small molecule therapeutics improving targeted radionuclide therapy outcomes in mCRPC
  • 5.3. Deployment of next generation digital PET/CT scanners enhancing image resolution and quantitative accuracy in prostate cancer diagnostics
  • 5.4. Regulatory approval and commercialization of novel radionuclide conjugates targeting PSMA for theranostic applications in prostate cancer patients
  • 5.5. Growth of hybrid PET/MRI systems to reduce radiation exposure while improving soft tissue characterization in prostate imaging
  • 5.6. Emergence of artificial intelligence algorithms for automated interpretation and prognostic risk stratification in prostate cancer nuclear scans
  • 5.7. Increasing adoption of personalized dosimetry software for optimizing safety and efficacy of lutetium-177 radioligand therapy in clinical practice
  • 5.8. Collaborations between academic institutions and pharma companies accelerating clinical trials of novel alpha-emitting PSMA therapies in prostate cancer management

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Prostate Cancer Nuclear Medicine Diagnostics Market, by Radiopharmaceutical

  • 8.1. 11C Choline
  • 8.2. 18F DcfpyL
  • 8.3. 18F Fluciclovine
  • 8.4. 68Ga Psma
  • 8.5. Emerging Agents
    • 8.5.1. 18F Psma 1007
    • 8.5.2. 64Cu Psma

9. Prostate Cancer Nuclear Medicine Diagnostics Market, by Modality

  • 9.1. Pet
    • 9.1.1. Digital Pet
    • 9.1.2. Time Of Flight Pet
  • 9.2. Spect
    • 9.2.1. Conventional Spect
    • 9.2.2. Spect Ct

10. Prostate Cancer Nuclear Medicine Diagnostics Market, by End User

  • 10.1. Academic Research Institute
  • 10.2. Diagnostic Center
  • 10.3. Hospital

11. Prostate Cancer Nuclear Medicine Diagnostics Market, by Indication

  • 11.1. Biochemical Recurrence Detection
  • 11.2. Initial Staging
  • 11.3. Treatment Monitoring

12. Prostate Cancer Nuclear Medicine Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Prostate Cancer Nuclear Medicine Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Prostate Cancer Nuclear Medicine Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. GE HealthCare Technologies Inc.
    • 15.3.2. Siemens Healthineers AG
    • 15.3.3. Koninklijke Philips N.V.
    • 15.3.4. Cardinal Health, Inc.
    • 15.3.5. Bayer AG
    • 15.3.6. Lantheus Holdings, Inc.
    • 15.3.7. Bracco Imaging S.p.A.
    • 15.3.8. Telix Pharmaceuticals Limited
    • 15.3.9. Eckert & Ziegler Strahlen- und Medizintechnik AG
    • 15.3.10. Isotope Technologies Munich SE

LIST OF FIGURES

  • FIGURE 1. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 11C CHOLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 11C CHOLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 11C CHOLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 11C CHOLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 11C CHOLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 11C CHOLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F DCFPYL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F DCFPYL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F DCFPYL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F DCFPYL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F DCFPYL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F DCFPYL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F FLUCICLOVINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F FLUCICLOVINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F FLUCICLOVINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F FLUCICLOVINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F FLUCICLOVINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F FLUCICLOVINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 68GA PSMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 68GA PSMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 68GA PSMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 68GA PSMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 68GA PSMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 68GA PSMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F PSMA 1007, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F PSMA 1007, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F PSMA 1007, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F PSMA 1007, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F PSMA 1007, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F PSMA 1007, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 64CU PSMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 64CU PSMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 64CU PSMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 64CU PSMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 64CU PSMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 64CU PSMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIGITAL PET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIGITAL PET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIGITAL PET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIGITAL PET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIGITAL PET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIGITAL PET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TIME OF FLIGHT PET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TIME OF FLIGHT PET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TIME OF FLIGHT PET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TIME OF FLIGHT PET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TIME OF FLIGHT PET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TIME OF FLIGHT PET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL SPECT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL SPECT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL SPECT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL SPECT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL SPECT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL SPECT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT CT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT CT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT CT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT CT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT CT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT CT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL RECURRENCE DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL RECURRENCE DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL RECURRENCE DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL RECURRENCE DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL RECURRENCE DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL RECURRENCE DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INITIAL STAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INITIAL STAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INITIAL STAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INITIAL STAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INITIAL STAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INITIAL STAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TREATMENT MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TREATMENT MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TREATMENT MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TREATMENT MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. AS